Series: The T Files — Series 3: “The Injection Dark Ages"
Subtitle: 50 years of yo-yo shots, hormonal roller coasters, and the pharmacology nobody warned you about
Post: 1 of 5
Tags: testosterone propionate, TRT history, injectable testosterone, pharmacokinetics, half-life, hypogonadism
Word Count: ~1,100
The year is 1937. A German pharmaceutical company called Schering AG has just synthesized the first clinically usable injectable testosterone. It works. It genuinely works — men with hypogonadism are experiencing real improvements in libido, energy, and mood for the first time in medical history. There’s just one small problem.
To keep those benefits, a patient needs an injection every two to three days. For the rest of his life.
Welcome to testosterone propionate, the original injectable testosterone, and arguably the most demanding drug regimen ever inflicted on a patient who wasn’t actively being punished.
What Testosterone Propionate Actually Is
To understand why propionate is so relentless about its dosing schedule, you need a brief detour into ester chemistry — which sounds worse than it is.
Raw, unmodified testosterone injected into muscle has a half-life of approximately 10 minutes. That’s not a typo. The body clears it almost instantly, which would require you to essentially live at a clinic with an IV drip. Not practical.
To solve this, chemists in the 1930s learned to attach a chemical “ester” group to testosterone’s 17-beta carbon position. The ester acts like a slow-release coating: once injected into muscle tissue (usually in an oil carrier), the compound slowly releases testosterone as enzymes in the body cleave off the ester group. The longer and more complex the ester chain, the slower the release.
Testosterone propionate’s ester is short — just three carbon atoms. This makes it the simplest ester modification but also the most time-limited. The result is a half-life of roughly 20 hours, meaning meaningful serum testosterone begins declining significantly within about 24–36 hours of injection. By day three, a patient is functionally running on fumes.
This is not a design flaw anyone overlooked. It was simply the state of the science in the late 1930s. Propionate was a genuine breakthrough. It just happened to be a breakthrough with a very demanding upkeep schedule.
The Patient Experience: A Brutally Honest Reconstruction
Imagine being prescribed testosterone propionate in, say, 1945. You are a 42-year-old man with documented primary hypogonadism. Your physician has explained that this new therapy will restore your energy, libido, and sense of wellbeing. He has also explained — perhaps with less emphasis — that you will need to inject yourself every two to three days.
Every. Two. To. Three. Days.
For the 1940s patient, this meant intramuscular injections administered into the gluteal muscle — the buttock — using needles that were not the fine-gauge instruments we have today. The oil-based suspension (typically sesame or castor oil) required a larger bore needle to draw up and inject. The injection itself was a procedure, not a quick prick. Injection site pain was routine. Injection site irritation was common. And the entire exercise had to be repeated within 72 hours to prevent symptoms from returning.
There was also the roller coaster problem, which we’ll explore in detail in a later post — but even at two-to-three-day intervals, patients on propionate experienced fluctuating serum levels. They felt better in the 12–24 hours after injection as testosterone peaked. They felt progressively less well as it declined. Their libido, energy, and mood followed the pharmacokinetic curve with uncomfortable fidelity.
For men willing to endure this, propionate worked. For the many who found the schedule untenable — and there were many — TRT in its earliest form was effectively inaccessible.
Why It Remained in Clinical Use
Testosterone propionate’s demanding schedule didn’t kill it immediately, for a few reasons.
First, it was the only option for years. The longer-acting testosterone enanthate and testosterone cypionate weren’t developed until the 1950s. If you wanted TRT before that, propionate was it.
Second, propionate does have real clinical advantages in certain contexts. Its short half-life is actually a feature for patients who need rapid titration or who experience adverse effects — if something goes wrong, the testosterone clears quickly. For patients being closely monitored or transitioning between formulations, this reversibility matters.
Third, and somewhat poignantly, patients and physicians in the 1940s and 1950s had lower expectations for treatment convenience. Medicine was routinely inconvenient. Insulin-dependent diabetics injected themselves daily. Patients with serious conditions accepted serious treatment burdens. The idea that a therapy should be convenient was, to some extent, a luxury that came later.
The Pharmacokinetic Arithmetic That Made It Unsustainable
The fundamental problem with testosterone propionate was arithmetic. A half-life of approximately 20 hours means that after 40 hours (two half-lives), you’re at 25% of your peak serum level. After 60 hours, you’re at 12.5%. By day three, a significant portion of patients are dipping back into symptomatic hypogonadal territory.
Physicians prescribing propionate faced an unpleasant choice: dose frequently enough to maintain reasonably stable levels (every two to three days), or dose less frequently and accept that patients would cycle in and out of symptomatic ranges. Neither option was great.
The dosing range used clinically was typically 25–50mg every two to three days. Some protocols pushed the frequency toward every other day for patients who found the troughs symptomatic. That’s three to four injections per week, which, by any measure, is a treatment burden more appropriate for managing a serious acute illness than a chronic hormonal condition.
The Lasting Legacy
Testosterone propionate eventually fell out of favor for primary TRT use in most Western countries once longer-acting formulations became available. Testosterone enanthate and testosterone cypionate, with their dramatically longer half-lives, made every-two-to-four-week dosing possible and quickly dominated the market from the 1950s onward.
Propionate didn’t disappear entirely. It remained (and remains) in clinical use in parts of Europe and is occasionally employed for specific clinical scenarios requiring rapid-acting testosterone or fast clearance. In the bodybuilding and performance enhancement community, it developed a following precisely because of its short half-life — a dubious honor, but a form of legacy nonetheless.
The more important legacy is what propionate taught the field: that half-life engineering mattered enormously. The pharmacokinetic properties of a testosterone formulation didn’t just determine dosing convenience — they determined whether patients would actually stay on treatment. A drug that requires an injection every two to three days forever will, predictably, have adherence problems. This lesson would take the field another fifty years to fully internalize.
In the meantime, the next generation of injectables offered a solution to the frequency problem. Unfortunately, as we’ll see in the next post, they introduced a new one.
Next time: Testosterone enanthate became the dominant injectable form for nearly five decades — 50 to 400mg every two to four weeks, administered by millions of men worldwide. The good news: far fewer injections. The bad news: what goes up supratherapeutically at 36–48 hours tends to come crashing down subtherapeutically by week three. The era of the hormonal roller coaster begins.
